Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and.
SAN ANTONIO - bioAffinity Technologies, Inc. , a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the.
bioAffinity (BIAF) Announces CMS Posts Final Payment Determination for CyPath Lung Effective January 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
30.11.2023 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) . Seite 1
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the United States for the PromarkerD predictive test for diabetic kidney disease.